CHRM3
ENSG00000133019
Target class
GPCR
Chromosome
1
Approved drugs
39
Clinical candidates (approved and in development)
50
- Approved drugs
- 39
- Clinical candidates (approved and in development)
- 50
- Chemical probe available
- Yes
- Other names
- m3AChR
- Target name
- CHRM3
- Gene name
- Cholinergic receptor muscarinic 3
- Gene symbol
- CHRM3
- Protein name
- Muscarinic acetylcholine receptor M3
- Gene biotype
- Protein coding
- Gene family
- Cholinergic receptors muscarinic
- Target class
- GPCR
- Target type
- Human gene
- Tissues expressed in
- 21
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 12.44
- Tissue specificity (Gini)
- 0.688
- Tissue specificity (tau)
- 0.863
- KEGG gene identifiers
- hsa:1131
- Protein interaction confidence
- 0.875
- Protein interaction partners
- 9
- R-HSA-390648
- R-HSA-399997
- R-HSA-416476
- End position
- 239915452
- Start position
- 239386513
- Chromosome
- 1
- Strand
- Forward
- Cell membrane
- Multi-pass membrane protein . Postsynaptic cell membrane
- Multi-pass membrane protein . Basolateral cell membrane
- Multi-pass membrane protein . Endoplasmic reticulum membrane
- Multi-pass membrane protein . Note=Colocalizes with TMEM147 in the endoplasmic reticulum (ER) membrane. TMEM147 impairs its trafficking to the cell membrane leading to its retention in the ER membrane. .
- Plasma membrane
- PubMed 21056967
- PubMed 15870063
- Tissue specificity (tau)
- 0.863071
- Expression inequality (Gini)
- 0.68759
Expression in transcripts per million
- Esophagus - Muscularis
- 12.44
- Esophagus - Gastroesophageal Junction
- 11.17
- Colon - Sigmoid
- 9.31
- Brain - Frontal Cortex (BA9)
- 8.99
- Bladder
- 8.17
Expression in transcripts per million
- Esophagus - Muscularis12.44
- Esophagus - Gastroesophageal Junction11.17
- Colon - Sigmoid9.31
- Brain - Frontal Cortex (BA9)8.99
- Bladder8.17
- Brain - Cortex6.65
- Minor Salivary Gland5.14
- Stomach5.08
- Brain - Anterior cingulate cortex (BA24)4.16
- Pancreas3.76
- Colon - Transverse3.33
- Ovary2.38
- Thyroid1.74
- Uterus1.38
- Brain - Amygdala1.21
- Skin - Sun Exposed (Lower leg)1.17
- Brain - Hippocampus1.15
- Brain - Hypothalamus1.09
- Small Intestine - Terminal Ileum1.08
- Brain - Putamen (basal ganglia)1.04
- Esophagus - Mucosa1.04
- Artery - Coronary0.97
- Brain - Caudate (basal ganglia)0.95
- Testis0.8
- Skin - Not Sun Exposed (Suprapubic)0.77
And 29 more, listed on the interactive page.
- GO:0007165
- GO:0007186
- GO:0007399
- GO:0019722
- GO:0036211
- GO:0095500
- GO:0005789
- GO:0005886
- GO:0009925
- GO:0016323
- GO:0004435
- GO:0005515
- GO:0016907
- GO:0038023
exhaustion
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: exhaustion
- nervous system
- respiratory
- liver
- cardiovascular
- gastrointestinal
PubMed 28216264abdominal cramps
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: abdominal cramps
- nervous system
- respiratory
- liver
- cardiovascular
- gastrointestinal
PubMed 28216264constipation
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: constipation
- nervous system
- respiratory
- liver
- cardiovascular
- gastrointestinal
PubMed 28216264increased/decreased blood pressure
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: increased/decreased blood pressure
- nervous system
- respiratory
- liver
- cardiovascular
- gastrointestinal
PubMed 28216264increased body temperature
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: increased body temperature
- nervous system
- respiratory
- liver
- cardiovascular
- gastrointestinal
PubMed 28216264frothing
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: frothing
- nervous system
- respiratory
- liver
- cardiovascular
- gastrointestinal
PubMed 28216264decreased salivation
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: decreased salivation
- nervous system
- respiratory
- liver
- cardiovascular
- gastrointestinal
PubMed 28216264dry mouth
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: dry mouth
- nervous system
- respiratory
- liver
- cardiovascular
- gastrointestinal
PubMed 28216264liver failure
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: liver failure
- nervous system
- respiratory
- liver
- cardiovascular
- gastrointestinal
PubMed 28216264bronchorrhea
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: bronchorrhea
- nervous system
- respiratory
- liver
- cardiovascular
- gastrointestinal
PubMed 28216264diarrhea
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: diarrhea
- nervous system
- respiratory
- liver
- cardiovascular
- gastrointestinal
PubMed 28216264blurred vision
- Inhibition/Decrease/Downregulation: acute
- Activation/Increase/Upregulation: acute
Studies
- preclinical: blurred vision
- nervous system
- respiratory
- liver
- cardiovascular
- gastrointestinal
PubMed 28216264decreased intestinal transit
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: decreased intestinal transit
- nervous system
- respiratory
- liver
- cardiovascular
- gastrointestinal
PubMed 28216264decreased gastric emptying
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: decreased gastric emptying
- nervous system
- respiratory
- liver
- cardiovascular
- gastrointestinal
PubMed 28216264lacrimation
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: lacrimation
- nervous system
- respiratory
- liver
- cardiovascular
- gastrointestinal
PubMed 28216264irritability
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: irritability
- nervous system
- respiratory
- liver
- cardiovascular
- gastrointestinal
PubMed 28216264pleural effusions
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: pleural effusions
- nervous system
- respiratory
- liver
- cardiovascular
- gastrointestinal
PubMed 28216264cough
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: cough
- nervous system
- respiratory
- liver
- cardiovascular
- gastrointestinal
PubMed 28216264increased salivation
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: increased salivation
- nervous system
- respiratory
- liver
- cardiovascular
- gastrointestinal
PubMed 28216264increased pupil diameter
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: increased pupil diameter
- nervous system
- respiratory
- liver
- cardiovascular
- gastrointestinal
PubMed 28216264muscle cramps
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: muscle cramps
- nervous system
- respiratory
- liver
- cardiovascular
- gastrointestinal
PubMed 28216264centrilobular liver congestion
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: centrilobular liver congestion
- nervous system
- respiratory
- liver
- cardiovascular
- gastrointestinal
PubMed 28216264decreased pupil diameter
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased pupil diameter
- nervous system
- respiratory
- liver
- cardiovascular
- gastrointestinal
PubMed 28216264ptosis
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: ptosis
- nervous system
- respiratory
- liver
- cardiovascular
- gastrointestinal
PubMed 28216264bronchospasm
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: bronchospasm
- nervous system
- respiratory
- liver
- cardiovascular
- gastrointestinal
PubMed 28216264
And 6 more, listed on the interactive page.
dry mouth
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- preclinical: dry mouth
- pulmonary
- gastrointestinal
PubMed 23197038blurred vision
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- preclinical: blurred vision
- pulmonary
- gastrointestinal
PubMed 23197038urinary smooth muscle constriction
Effects
- Activation/Increase/Upregulation: general
Studies
- preclinical: urinary smooth muscle constriction
- pulmonary
- gastrointestinal
PubMed 23197038bronchoconstriction
Effects
- Activation/Increase/Upregulation: general
Studies
- preclinical: bronchoconstriction
- pulmonary
- gastrointestinal
PubMed 23197038gastrointestinal smooth muscle constriction
Effects
- Activation/Increase/Upregulation: general
Studies
- preclinical: gastrointestinal smooth muscle constriction
- pulmonary
- gastrointestinal
PubMed 23197038constipation
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- preclinical: constipation
- pulmonary
- gastrointestinal
PubMed 23197038receptor binding
Studies
- biochemical: NVS_GPCR_hM3, is one of one assay component(s) measured or calculated from the NVS_GPCR_hM3 assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.
Biological samples
- cell-free
Evidence sourceincreased salivation
Effects
- Activation/Increase/Upregulation: general
Studies
- preclinical: increased salivation
- pulmonary
- gastrointestinal
PubMed 23197038pupil dilation
Effects
- Inhibition/Decrease/Downregulation: general
Studies
- preclinical: pupil dilation
- pulmonary
- gastrointestinal
PubMed 23197038
Related records
Trials (1,656)
- : Vascular Function in Health and Disease
- "Death Rattle" - A Double Blind, Randomly Controlled, Crossover Trial
- "Low Dose Sugammadex Combined With Neostigmine and Glycopyrrolate Versus Full Dose Sugammadex for Reversal of Rocuronium-induced Neuromuscular Blockade: a Cost Saving Strategy"
- 0.6 vs. 1.2 mg Atropine Together With Neostigmine 2.5 mg on Heart Rate in Patient Receiving Muscle Relaxant
- 1-year Study to Assess the Efficacy, Safety, and Tolerability of Glycopyrronium Bromide (NVA237) in Chronic Obstructive Pulmonary Disease (COPD)
- 12 Week Efficacy of Tiotropium Versus Placebo in Patients With Mild COPD According to Swedish Guidelines (SPIRIMILD)
- 12-week Treatment With Inhaled Tiotropium (18 mcg Once Daily) on Lung Function and Static Lung Volumes in Stable, Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Patients. Correlation to Dyspnoea Scales
- 129-Xe MRI Study of Single Triple Therapy Inhaler Effects in COPD Patients With Moderate-severe Dyspnea and/or Poor Health Status With High or Low Risk of Exacerbation
- 24-hour Lung Function in Subjects With Moderate to Very Severe COPD After Treatment With PT003, Open-Label Spiriva® Respimat® as an Active Control, and Placebo
- 24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease
- 24-week Trial Comparing GSK573719/GW642444 With GW642444 and With Tiotropium in Chronic Obstructive Pulmonary Disease
- 24hr Effects of Tiotropium Bromide in Tetraplegia
- 26 Week Efficacy, Safety and Tolerability Study of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)
- 28-day Repeat Dose Study of GSK573719
- 7 Days of TD-4208 in Subjects With Chronic Obstructive Pulmonary Disease
- A 12 Week Study to Confirm the Effectiveness of 8mg of Fesoterodine Compared to 4mg of Fesoterodine
- A 12 Week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation.
- A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium 62.5 Microgram (mcg) Compared With Glycopyrronium 44 mcg in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
- A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium Compared With Tiotropium in Subjects With Chronic Obstructive Pulmonary Disease
- A 12-Week Study to Evaluate the Efficacy of Darifenacin to Increase the Warning Time in Patients With Overactive Bladder.
Drugs (81)
- Acetylcholine Muscarinic acetylcholine receptor M3 agonist
- Acetylcholine chloride Muscarinic acetylcholine receptor M3 agonist
- Aclidinium Muscarinic acetylcholine receptor M3 antagonist
- Aclidinium bromide Muscarinic acetylcholine receptor M3 antagonist
- Afacifenacin Muscarinic acetylcholine receptor antagonist
- Anisotropine Muscarinic acetylcholine receptor M3 antagonist
- Anisotropine methylbromide Muscarinic acetylcholine receptor M3 antagonist
- ASM-024 Muscarinic acetylcholine receptor M3 antagonist
- Atropine Muscarinic acetylcholine receptor M3 antagonist
- Atropine sulfate Muscarinic acetylcholine receptor M3 antagonist
- AZD-9164 Muscarinic acetylcholine receptor M3 antagonist
- AZD8683 Muscarinic acetylcholine receptor M3 antagonist
- Batefenterol Muscarinic acetylcholine receptor M3 antagonist
- Bethanechol Muscarinic acetylcholine receptor M3 agonist
- Bethanechol chloride Muscarinic acetylcholine receptor M3 agonist
- Carbachol Muscarinic acetylcholine receptor M3 agonist
- Carbamoylcholine Muscarinic acetylcholine receptor M3 agonist
- Cevimeline Muscarinic acetylcholine receptor M3 agonist
- Cevimeline hydrochloride Muscarinic acetylcholine receptor M3 agonist
- Clidinium Muscarinic acetylcholine receptor M3 antagonist